The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients using GnRH analogues for endometriosis it has been postulated that peripheral and inflammation-induced in-situ aromatization of adrenal androgens are probably the main reasons for the high rates of failure during follow-up. We hypothesized that in cases with premenopausal severe endometriosis, use of a combination of anastrozole and goserelin to achieve almost maximal endocrine blockade of estrogen synthesis after conservative surgery may increase the pain-free interval and reduce the recurrence rates as compared to goserelin alone. METHODS: In a prospective randomized trial, we evaluated the efficacy of using either a combination of anastrozole and goserelin for 6 months or goserelin alone for 6 months after conservative surgery for severe endometriosis. The primary outcome measures were the symptom recurrence rates and the impact of treatment on endometriosis-related multidimensional score. The secondary outcome measures were the impact of allocated treatment regimens on menopausal quality of life and on lumbar spine bone mineral density (BMD). RESULTS: When we analyzed the Kaplan-Meier survival curves, we detected a statistically significant advantage of goserelin plus anastrozole as compared to goserelin only, in terms of the median time to detect symptom recurrence (>2.4 versus 1.7 months; log-rank test; P=0.0089). This statistically significant advantage occurred with a relative risk of 4.3 [95% confidence interval (CI) 1.3-9.8]. Three cases out of 40 recurred in the goserelin plus anastrozole arm (7.5%), whereas we detected recurrences in 14 cases out of 40 cases in the goserelin-only arm (35%) during the follow-up period of 24 months. Based on these data, the interpretation of Kaplan-Meier curves indicates that at the end of follow-up, 54.7 versus 10.4%, respectively, of the patients were free of recurrence. The mean of the differences in terms of Deltabaseline-24 months post-medical therapy multidimensional score were statistically significant in favour of goserelin and anastrozole (9.2 +/- 2.1 versus 6.7 +/- 2.8; paired t-test; P<0.0001; 95% CI 1.5-4.0). We observed a statistically significant difference in suppression of estradiol concentrations and a significantly greater BMD loss at the end of treatment in the goserelin and anastrozole arm as compared to goserelin-only arm. However, this did not elicit deterioration in menopausal quality of life and the observed bone loss was not significant in terms of DeltaBMD between the groups at 2 years of treatment withdrawal. CONCLUSIONS: Six months of treatment with anastrozole and goserelin as compared to goserelin alone increased the pain-free interval and decreased symptom recurrence rates in patients following surgery for severe endometriosis. Furthermore, menopausal quality of life and BMD at 2 years after medical therapy remained unaffected.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Only one study, showed a longer interval before recurrence of symptoms during the 24-month follow-up: recurrence was registered in only 3/40 (8%) of patients in the combined arm (AI + goserelin) compared to 14/40 (35%) in the goserelin-only arm ( 26 ).”
From Is intracrinology of endometriosis relevant in clinical practice? A systematic review on estrogen metabolism (2022) · cites this paper as [26]
In the citing paper
“Anastrozole (1 mg/day), administered in conjunction with goserelin for 6 months in patients with severe baseline endometriosis (rASRM score >40), showed greater improvement in pain Total Pelvic Symptom Score (TPSS) than patients using goserelin alone (ΔTPSS-P baseline -24 months PMT 5.0 vs. 3.3 p<0.0001) ( 26 ).”
From Is intracrinology of endometriosis relevant in clinical practice? A systematic review on estrogen metabolism (2022) · cites this paper as [26]
Citations
Cites
Revised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
ASSESSMENT OF FRACTURE RISK AND ITS APPLICATION TO SCREENING FOR POSTMENOPAUSAL OSTEOPOROSIS
Alexeeva, L. P., Burkhardt, P., Christiansen, C., Cooper, C. C., Delmas, P. D., Johnell, O., Johnston, C. C., Kanis, J. A., Lips, P. T. A. M., Melton, L. J., et al. (1994) · Cited by 2,655
Mitwally, M. F. M., & Casper, R. F. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01705-2 · Cited by 800 · cited 2×
“Aromatase inhibitors given alone are not able to completely inhibit ovarian steroidogenesis (Vignali et al., 2002), and, furthermore, may increase follicular recruitment (Mitwally and Casper, 2001) and may lead to ovarian stimulation and cyst formation.”
BackgroundInfluentialConstructing a standard climacteric scale
Greene, J. G. (1998) · Maturitas · doi:10.1016/s0378-5122(98)00025-5 · Cited by 657 · cited 2×
“The modi®ed Greene scale was used to determine the severity of vasomotor, somatic, psychological symptoms (anxiety and depression) and loss of sexual interest (Greene, 1998).”
MethodDeterminants of bone density in normal women: risk factors for future osteoporosis?
Stevenson, J. C., Lees, B., Devenport, M., Cust, M. P., & Ganger, K. F. (1989) · BMJ · doi:10.1136/bmj.298.6678.924 · Cited by 406 · cited 2×
“Furthermore, the physiological bone loss of 0.5% per year that is evident after the third decade should also be taken into account (Stevenson et al., 1989).”
BackgroundInfluentialTreatment of severe postmenopausal endometriosis with an aromatase inhibitor
Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00022-3 · Cited by 270 · cited 4×
“In the statistical analysis of the secondary outcome variables, intentionto-treat analysis (Archer and Pickar, 2002) was used; thus, it included the dropouts for whom data are not available at 24 months after postsurgical medical treatment.”
BackgroundMethodInfluentialDosage aspects of danazol therapy in endometriosis: Short-term and long-term effectiveness
Biberoglu, K. O., & Behrman, S. J. (1981) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(81)90478-6 · Cited by 267 · cited 2×
“…it is recommended that postoperative adjuvant treatment should be instituted in order to minimize the risk of recurrence and to extend the pain-free period after conservative surgery in cases of severe endometriosis (American College of Obstetrics and Gynecology, 1999; Gambone et al., 2002).”
BackgroundMethodAromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target
Zeitoun, K. M., & Bulun, S. E. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(99)00393-3 · Cited by 256 · cited 2×
“In the statistical analysis of the secondary outcome variables, intentionto-treat analysis (Archer and Pickar, 2002) was used; thus, it included the dropouts for whom data are not available at 24 months after postsurgical medical treatment.”
MethodCompston, J. (1995) · Annals of the Rheumatic Diseases · doi:10.1136/ard.54.7.548 · Cited by 252
LING, F. W. (1999) · Obstetrics & Gynecology · doi:10.1097/00006250-199901000-00012 · Cited by 223 · cited 2×
“necessary in accordance with the recent literature (Hornstein et al., 1997; American College of Obstetrics and Gynecology, 1999; Ling, 1999; Vercellini et al., 1999; Winkel, 2000; Gambone et al., 2002).”
Result
Cited by
Giudice, L. C., & Kao, L. C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17403-5 · Cited by 3,166
Endometriosis: pathogenesis and treatment
Vercellini, P., Viganò, P., Somigliana, E., & Fedele, L. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.255 · Cited by 1,940
Bulun, S. E. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804690 · Cited by 1,772
Bulun, S. E., Yilmaz, B. D., Sison, C., Miyazaki, K., Bernardi, L., Liu, S., Kohlmeier, A., Yin, P., Milad, M., & Wei, J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00242 · Cited by 844
Recurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
Metadata
- Authors
- Soysal, S.
- Affiliations
- Pamukkale Üniversitesi Hastaneleri (TR)
- Corresponding author
- Soysal, S.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-01-01
- Volume
- 19
- Issue
- 1
- Pages
- 160-167
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2149342667
- Cited by
- 227
- References
- 24
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 12 · 2023: 6 · 2022: 5 · 2021: 8 · 2020: 5 · 2019: 8 · 2018: 9 · 2017: 8 · 2016: 10 · 2015: 10 · 2014: 7 · 2013: 10 · 2012: 12
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Human Reproduction (publishedVersion)
- PubMed (publishedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Keywords
- endometriosis, goserelin, anastrozole, GnRH analogues, aromatase inhibitors, combination endocrine therapy, conservative surgery, symptom recurrence, bone mineral density, lumbar spine, estrogen synthesis, premenopausal women
- MeSH terms
- Anastrozole, Adult, Drug Administration Schedule, Drug Therapy, Combination, Endometriosis, Enzyme Inhibitors, Estradiol, Female, Humans, Menopause, Nitriles, Palliative Care, Postoperative Care, Quality of Life, Severity of Illness Index, Triazoles, Bone Density, Survival Analysis, Treatment Outcome, Goserelin, Patient Selection, Aromatase Inhibitors, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. https://app.cochat.ai/papers/10.1093/humrep/deh035
- The paper
- Soysal, S. (2004). The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Human Reproduction. https://doi.org/10.1093/humrep/deh035
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.